JP2017519784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519784A5 JP2017519784A5 JP2016575488A JP2016575488A JP2017519784A5 JP 2017519784 A5 JP2017519784 A5 JP 2017519784A5 JP 2016575488 A JP2016575488 A JP 2016575488A JP 2016575488 A JP2016575488 A JP 2016575488A JP 2017519784 A5 JP2017519784 A5 JP 2017519784A5
- Authority
- JP
- Japan
- Prior art keywords
- linked
- pharmaceutical composition
- composition according
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 86
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 25
- -1 α-amino acid ester Chemical class 0.000 claims 24
- 235000008206 alpha-amino acids Nutrition 0.000 claims 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 10
- 235000004279 alanine Nutrition 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 239000004474 valine Substances 0.000 claims 10
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 9
- 239000004475 Arginine Substances 0.000 claims 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 8
- 239000004471 Glycine Substances 0.000 claims 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000004472 Lysine Substances 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- 239000004473 Threonine Substances 0.000 claims 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 8
- 235000009582 asparagine Nutrition 0.000 claims 8
- 229960001230 asparagine Drugs 0.000 claims 8
- 235000018417 cysteine Nutrition 0.000 claims 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 8
- 229930195712 glutamate Natural products 0.000 claims 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 8
- 229930182817 methionine Natural products 0.000 claims 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 125000005907 alkyl ester group Chemical group 0.000 claims 6
- 229940009098 aspartate Drugs 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 150000007860 aryl ester derivatives Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241001122120 Hepeviridae Species 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 102220587413 N-acetylserotonin O-methyltransferase-like protein_R23A_mutation Human genes 0.000 claims 1
- 102220587418 N-acetylserotonin O-methyltransferase-like protein_R24A_mutation Human genes 0.000 claims 1
- 102220479492 NAD(+) hydrolase SARM1_R22A_mutation Human genes 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- FYGSULGPSNHJFD-LUTQBAROSA-N C#C[C@@]([C@@H]1O)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)F Chemical compound C#C[C@@]([C@@H]1O)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)F FYGSULGPSNHJFD-LUTQBAROSA-N 0.000 description 1
- MAYPBRYPGCIUGY-FPQZTECRSA-N CC([C@@]([C@@H]1F)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)O)=C Chemical compound CC([C@@]([C@@H]1F)([C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@@]1(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)F)O)=C MAYPBRYPGCIUGY-FPQZTECRSA-N 0.000 description 1
- GRVAKIGJYFCAOR-LGVRLFTQSA-N CCOc1c2nc[n]([C@@H]([C@]3(C)F)OCC3(COP(NC(C)C(OC(C)C)=O)(Oc3ccccc3)=O)O)c2nc(N)n1 Chemical compound CCOc1c2nc[n]([C@@H]([C@]3(C)F)OCC3(COP(NC(C)C(OC(C)C)=O)(Oc3ccccc3)=O)O)c2nc(N)n1 GRVAKIGJYFCAOR-LGVRLFTQSA-N 0.000 description 1
- POYJEGXPYNEDOC-OUVAMTEUSA-N CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@](C)([C@@H]1F)O)O[C@@]1(COP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)F Chemical compound CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@](C)([C@@H]1F)O)O[C@@]1(COP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)F POYJEGXPYNEDOC-OUVAMTEUSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016232P | 2014-06-24 | 2014-06-24 | |
| US62/016,232 | 2014-06-24 | ||
| US201462061770P | 2014-10-09 | 2014-10-09 | |
| US62/061,770 | 2014-10-09 | ||
| PCT/US2015/037001 WO2015200219A1 (en) | 2014-06-24 | 2015-06-22 | Substituted nucleosides, nucleotides and analogs thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114136A Division JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519784A JP2017519784A (ja) | 2017-07-20 |
| JP2017519784A5 true JP2017519784A5 (enExample) | 2018-09-13 |
| JP6728075B2 JP6728075B2 (ja) | 2020-07-22 |
Family
ID=54868668
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575488A Active JP6728075B2 (ja) | 2014-06-24 | 2015-06-22 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2020114136A Active JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2022085181A Active JP7449978B2 (ja) | 2014-06-24 | 2022-05-25 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114136A Active JP7080928B2 (ja) | 2014-06-24 | 2020-07-01 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
| JP2022085181A Active JP7449978B2 (ja) | 2014-06-24 | 2022-05-25 | 置換ヌクレオシド、ヌクレオチドおよびその類似体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9603864B2 (enExample) |
| EP (2) | EP3160476B1 (enExample) |
| JP (3) | JP6728075B2 (enExample) |
| CN (2) | CN106573011A (enExample) |
| AU (2) | AU2015280248B2 (enExample) |
| CA (2) | CA3207106A1 (enExample) |
| DK (1) | DK3160476T3 (enExample) |
| EA (1) | EA201692535A1 (enExample) |
| ES (1) | ES2841310T3 (enExample) |
| HR (1) | HRP20202014T1 (enExample) |
| HU (1) | HUE051986T2 (enExample) |
| IL (1) | IL249628A0 (enExample) |
| LT (1) | LT3160476T (enExample) |
| MX (1) | MX2016017383A (enExample) |
| PH (1) | PH12016502564A1 (enExample) |
| SG (1) | SG11201610599TA (enExample) |
| SI (1) | SI3160476T1 (enExample) |
| SM (1) | SMT202000716T1 (enExample) |
| TW (1) | TW201613612A (enExample) |
| WO (1) | WO2015200219A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6284547B2 (ja) * | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9815864B2 (en) | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3055319A4 (en) * | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
| US9603863B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3197457B1 (en) * | 2014-09-26 | 2022-11-09 | Riboscience LLC | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| MY190867A (en) * | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| FI3433257T3 (fi) * | 2016-03-24 | 2024-01-08 | Novartis Ag | Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| JP7125144B2 (ja) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US11643432B2 (en) | 2016-12-16 | 2023-05-09 | National University Corporation Tokai National Higher Education And Research System | Nucleoside derivative and use thereof |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| ES3000461T3 (en) | 2017-07-11 | 2025-02-28 | Gilead Sciences Inc | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| JP2020529994A (ja) | 2017-07-31 | 2020-10-15 | ジャニュアリー セラピューティクス，インク． | 有機リン酸誘導体 |
| KR102696517B1 (ko) | 2017-09-18 | 2024-08-21 | 얀센 바이오파마, 인크. | 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체 |
| CA3080896A1 (en) | 2017-10-31 | 2019-05-09 | Yamasa Corporation | Nucleoside derivative and use thereof |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| CA3092834A1 (en) * | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
| KR20200140274A (ko) * | 2018-03-07 | 2020-12-15 | 에모리 유니버시티 | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| PH12021500034A1 (en) | 2019-03-06 | 2022-06-06 | Glaxosmithkline Ip No 2 Ltd | Compounds useful in hiv therapy |
| CN113710680B (zh) * | 2019-04-05 | 2025-01-24 | 株式会社日本触媒 | 交联型人工核苷的制备 |
| CA3153281A1 (en) * | 2019-10-08 | 2021-07-08 | George R. Painter | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| AR121356A1 (es) * | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN113387954B (zh) * | 2020-03-11 | 2024-03-19 | 上海特化医药科技有限公司 | 一种瑞德西韦中间体的制备方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| EP4125912B1 (en) * | 2020-03-27 | 2025-07-30 | R.G.C.C. Holdings AG | Compounds for the in vitro inhibition of the rna-dependent rna polymerase of coronaviruses |
| JP7698631B2 (ja) * | 2020-03-27 | 2025-06-25 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| KR20230002592A (ko) * | 2020-04-14 | 2023-01-05 | 얀센 파마슈티칼즈, 인코포레이티드 | E형 간염의 치료를 위한 바이사이클릭 및 모노사이클릭 뉴클레오시드 유사체 |
| TW202532084A (zh) | 2020-05-29 | 2025-08-16 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| US11773122B2 (en) | 2020-08-24 | 2023-10-03 | Gilead Sciences. Inc. | Phospholipid compounds and uses thereof |
| PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| CN112279877B (zh) * | 2020-12-15 | 2021-08-06 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法 |
| CN113214320A (zh) * | 2021-01-23 | 2021-08-06 | 河南泰丰生物科技有限公司 | 一种瑞德西韦化合物的制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| BR112023020798A2 (pt) * | 2021-04-09 | 2023-12-19 | Univ Emory | Método para tratar ou prevenir uma infecção, e, uso de um composto |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN113735929A (zh) * | 2021-07-21 | 2021-12-03 | 海化生命(厦门)科技有限公司 | 一种抗冠状病毒的化合物及其制备方法与应用 |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN115721661A (zh) * | 2021-09-01 | 2023-03-03 | 常晓宇 | 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途 |
| CN113461760B (zh) * | 2021-09-06 | 2021-12-10 | 南京颐媛生物医学研究院有限公司 | 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| US20250223588A1 (en) * | 2021-10-19 | 2025-07-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| IL315480A (en) | 2022-03-15 | 2024-11-01 | Rome Therapeutics Inc | Compounds and methods for treating disease |
| WO2023202604A1 (zh) * | 2022-04-20 | 2023-10-26 | 中国科学院上海药物研究所 | 抗病毒核苷类似物及其药物组合物和用途 |
| WO2024034644A1 (ja) * | 2022-08-10 | 2024-02-15 | 国立大学法人九州大学 | 核酸前駆体 |
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN116589510B (zh) * | 2023-04-20 | 2025-08-26 | 安徽大学 | 一种氟代苄基核糖中间体的制备方法与应用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| TW200500375A (en) * | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2006033709A2 (en) * | 2004-07-29 | 2006-03-30 | Metabasis Therapeutics, Inc. | Novel nucleoside derivatives |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP5539735B2 (ja) * | 2007-02-28 | 2014-07-02 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | ウイルス感染の予防又は治療のための化合物とその使用方法 |
| WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| US20100240604A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| EP2623104A1 (en) * | 2009-03-20 | 2013-08-07 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CN102558261A (zh) * | 2010-12-17 | 2012-07-11 | 中国科学院大连化学物理研究所 | 一种核苷酸类似物及其合成和应用 |
| AU2011349278C1 (en) | 2010-12-22 | 2017-01-19 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| BR112013029761A2 (pt) | 2011-05-19 | 2017-03-21 | Univ Emory | pró-drogas de monofosfato de purina para tratamento de infecções virais |
| US9108999B2 (en) | 2011-12-20 | 2015-08-18 | Riboscience Llc | 2′, 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| SG10201804571TA (en) | 2012-03-21 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| HK1203513A1 (en) | 2012-03-21 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Methods of preparing substituted nucleotide analogs |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| FR3000193B1 (fr) | 2012-12-20 | 2015-01-16 | Msc & Sgcc | Procede et dispositif de mesure de la verticalite sur un recipient |
| AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6284547B2 (ja) | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
| WO2014164533A1 (en) | 2013-03-11 | 2014-10-09 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| CN105705511A (zh) | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9815864B2 (en) | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| BR112016029994A2 (pt) | 2014-06-24 | 2017-08-22 | Alios Biopharma Inc | métodos de preparação de análogos de nucleotídeo substituídos |
| US9603863B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
| US20160022724A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| WO2016022464A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| EP3497111A2 (en) | 2016-08-12 | 2019-06-19 | Janssen BioPharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US20180117042A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2015
- 2015-06-22 CN CN201580045439.9A patent/CN106573011A/zh active Pending
- 2015-06-22 EP EP15812231.7A patent/EP3160476B1/en active Active
- 2015-06-22 HR HRP20202014TT patent/HRP20202014T1/hr unknown
- 2015-06-22 SI SI201531469T patent/SI3160476T1/sl unknown
- 2015-06-22 JP JP2016575488A patent/JP6728075B2/ja active Active
- 2015-06-22 WO PCT/US2015/037001 patent/WO2015200219A1/en not_active Ceased
- 2015-06-22 CA CA3207106A patent/CA3207106A1/en active Pending
- 2015-06-22 US US14/746,500 patent/US9603864B2/en active Active
- 2015-06-22 CN CN202310927143.6A patent/CN117379452A/zh active Pending
- 2015-06-22 SM SM20200716T patent/SMT202000716T1/it unknown
- 2015-06-22 ES ES15812231T patent/ES2841310T3/es active Active
- 2015-06-22 CA CA2952966A patent/CA2952966C/en active Active
- 2015-06-22 EP EP20192890.0A patent/EP3797782A1/en not_active Ceased
- 2015-06-22 MX MX2016017383A patent/MX2016017383A/es unknown
- 2015-06-22 AU AU2015280248A patent/AU2015280248B2/en active Active
- 2015-06-22 LT LTEP15812231.7T patent/LT3160476T/lt unknown
- 2015-06-22 HU HUE15812231A patent/HUE051986T2/hu unknown
- 2015-06-22 DK DK15812231.7T patent/DK3160476T3/da active
- 2015-06-22 EA EA201692535A patent/EA201692535A1/ru unknown
- 2015-06-22 SG SG11201610599TA patent/SG11201610599TA/en unknown
- 2015-06-24 TW TW104120371A patent/TW201613612A/zh unknown
-
2016
- 2016-12-18 IL IL249628A patent/IL249628A0/en unknown
- 2016-12-21 PH PH12016502564A patent/PH12016502564A1/en unknown
-
2017
- 2017-02-02 US US15/423,270 patent/US10307439B2/en active Active
-
2020
- 2020-07-01 JP JP2020114136A patent/JP7080928B2/ja active Active
-
2021
- 2021-07-08 AU AU2021204791A patent/AU2021204791B2/en active Active
-
2022
- 2022-05-25 JP JP2022085181A patent/JP7449978B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519784A5 (enExample) | ||
| JP2020172511A5 (enExample) | ||
| JP2012521359A5 (enExample) | ||
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| JP2025098020A5 (enExample) | ||
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| HRP20202014T1 (hr) | Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije | |
| CY1118246T1 (el) | Αναστολεις αντιγραφης ιων γριπης | |
| CY1114892T1 (el) | Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| JP2015510946A5 (enExample) | ||
| MX2014001497A (es) | Profarmacos de trepostinil enlazados a un portador. | |
| UA108221C2 (uk) | Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| CY1118726T1 (el) | Αναστολεις αντιγραφης ιων γριπης | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| JP2017515901A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| CA2753382C (en) | Hepatitis c virus inhibitors | |
| EA201291301A1 (ru) | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич | |
| JP2013537907A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER |